Rhythm Pharmaceuticals Inc.

NASDAQ:RYTM  
103.15
-1.08 (-1.04%)
7:49:18 PM EDT: $105.00 +1.85 (+1.79%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.78B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$50.71 Million
Adjusted EPS-$0.71
See more estimates
10-Day MA$100.82
50-Day MA$85.88
200-Day MA$65.13
See more pivots

Rhythm Pharmaceuticals Inc. Stock, NASDAQ:RYTM

222 Berkeley Street, 12th floor, Boston, Massachusetts 02116-3748
United States of America
Phone: +1.857.264.4280
Number of Employees: 283

Description

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.